对重度抑郁症药物基因组指导治疗的成本效益
Shahzad Ghanbarian1, Gavin W K Wong2, Mary Bunka2
1The Centre for Clinical Epidemiology and Evaluation (Ghanbarian, Wong, Bunka, Edwards, Cressman, Conte, Bryan), Vancouver Coastal Health Research Institute, and The School of Public and Population Health (Ghanbarian, Wong, Bunka, Edwards, Conte, Vijh, Bryan), University of British Columbia, Vancouver, BC; Faculty of Health Sciences (Cressman), Simon Fraser University, Burnaby, BC; Department of Family Practice (Price, Vijh), and Department of Physiatry (Schuetz), Faculty of Medicine, University of British Columbia, Vancouver, BC; Patient partner (Riches), Prince George, BC; Patient partner (Landry), New Westminster, BC; Psychology Department (Erickson), Fraser Health, New Westminster, BC; Centre for Health Services and Policy Research (McGrail, Peterson), and Departments of Physical Therapy (Hoens) and Medical Genetics (Austin), University of British Columbia, Vancouver, BC shahzad.ghanbarian@ubc.ca.
对主要抑郁症 (MDD) 的药物基因组测试显著降低了医疗保健成本,并改善了患者的治疗结果. 这种遗传方法增强了抗抑郁药的有效性,并最大限度地减少了不良影响,为心理健康治疗提供了一个具有成本效益的策略.
科学领域:
- 药物基因组学 药物基因组学
- 精神病学是一个精神病学.
- 卫生经济学 卫生经济学
背景情况:
- 药基因组测试可以识别影响抗抑郁药代谢的遗传变异.
- 这种测试可以提高治疗效率,并减少严重抑郁症 (MDD) 的不良影响.
研究的目的:
- 评估实施药物基因组测试的成本效益,以指导MDD患者的抗抑郁药物处方.
- 从公共支付者的角度评估长期的经济和健康影响.
主要方法:
- 为加拿大不列颠哥伦比亚省的MDD护理途径开发了一种离散时间微模拟模型.
- 该模型结合了患者特征,如代谢器表型,使用系统性审查和行政记录 (2015-2020) 的数据.
- 增量成本,寿命年和质量调整寿命年 (QALYs) 估计超过20年.
主要成果:
- 在BC的药物基因组测试预计可以节省9.56亿美元 (每名患者4926美元),并在20年内为每名患者产生0.381个QALY.
- 节约的主要原因是减少过渡到耐火抑郁症,这种病例减少了37%.
- 据估计,测试成本将在实施后大约两年内抵消.
结论:
- 药基因组测试以指导抗抑郁药的使用,为健康系统提供了显著的健康益处和显著的成本降低.
- 这种方法代表了一种有价值的,促进投资的战略,用于改善精神卫生保健的提供和结果.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
Antidepressant Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Drug Therapy
Antianxiety Medications


